2-acetylamino-4-oxo-valeric acid | 100911-41-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-acetylamino-4-oxo-valeric acid
• 英文别名: 2-Acetylamino-4-oxo-valeriansaeure；2-Acetamido-4-oxopentanoic acid
• CAS: 100911-41-9
• 化学式: C₇H₁₁NO₄
• 分子量: 173.169
• InChiKey: YXNUVQQLAIUUGG-UHFFFAOYSA-N

物化性质

• 熔点：
  125-127 °C
• 沸点：
  444.2±35.0 °C(Predicted)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-acetylamino-4-oxo-valeric acid 在 乙醇 、 碳酸氢钠 、 钯 作用下， 生成 2-acetylamino-4-(2,4-dinitro-anilino)-valeric acid
  参考文献：
  名称：

  放线菌的代谢产物第17部分Holomycin †

  摘要：

  黄色，亲脂性抗生素全霉素，C 7，H 6； O 2，N 2，S 2，是从放线菌菌株ETH的培养滤液中获得的。分离出17474，具有去-N-甲基-硫代果胶的IV组成。

  DOI：

  10.1002/hlca.19590420225
• 作为产物：
  描述：

  ethyl 2-acetamido-2-ethoxycarbonyl-4-methyl-4-pentenoic acid 在 sodium hydroxide 、 乙醇 、 臭氧 作用下， 生成 2-acetylamino-4-oxo-valeric acid
  参考文献：
  名称：

  The Structures of Thiolutin and Aureothricin, Antibiotics Containing a Unique Pyrrolinonodithiole Nucleus

  摘要：

  DOI：

  10.1021/ja01615a058

文献信息

• COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Sharma Shalini

  公开号：US20080027229A1

  公开（公告）日：2008-01-31

  Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

  本发明公开了用于治疗各种代谢性疾病的化合物，例如胰岛素抵抗综合征、糖尿病、高脂血症、脂肪肝疾病、消瘦、肥胖症、动脉粥样硬化和动脉硬化等。
• MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：Ancliff Rachael Anne

  公开号：US20090163495A1

  公开（公告）日：2009-06-25

  There are provided according to the invention, novel compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了新的化合物，化学式为（I），其中R1、R2、R3、R4、R5、X、a、b和Z的定义如规范中所述，制备它们的方法，包含它们的配方以及它们在治疗炎症性疾病中的应用。
• DRUG CONTAINING LIVER TARGETING SPECIFIC LIGAND AND THYROID HORMONE RECEPTOR AGONIST
  申请人：Kylonova (Xiamen) Biopharma Co., Ltd.

  公开号：EP3888685A1

  公开（公告）日：2021-10-06

  Provided is a drug containing a liver targeting specific ligand and a thyroid hormone receptor agonist in its structure, which is a new drug structure formed by linking the liver targeting specific ligand with the thyroid hormone receptor agonist through a branched chain, a linker and a linking chain. Thyroid hormone receptors (TRs) are divided into two subtypes, TR-α and TR-β, wherein, TR-β is mainly expressed in liver, and TR-α is mainly expressed in heart, nervous system, etc. In certain embodiments, it is envisaged that the provided drug has the action of liver targeting, can specifically bring the thyroid hormone receptor agonist into liver, without entering heart and other issues, and may thereby avoide side effects caused by the action of the thyroid hormone receptor agonist on other issues, and maintain its therapeutic efficacy in the treatment of lipid metabolism disorders and related complications.

  本发明提供了一种药物，其结构中含有肝脏靶向特异性配体和甲状腺激素受体激动剂，该药物是通过支链、连接体和连接链将肝脏靶向特异性配体和甲状腺激素受体激动剂连接在一起而形成的新型药物结构。甲状腺激素受体（TRs）分为TR-α和TR-β两种亚型，其中，TR-β主要在肝脏表达，TR-α主要在心脏、神经系统等表达。在某些实施方案中，可以设想所提供的药物具有肝脏靶向作用，可以特异性地将甲状腺激素受体激动剂带入肝脏，而不进入心脏等，从而可以避免甲状腺激素受体激动剂对其他问题的作用所引起的副作用，保持其在治疗脂质代谢紊乱及相关并发症方面的疗效。
• NOVEL COMPOUND AND APPLICATION THEREOF
  申请人：Kylonova (Xiamen) Biopharma Co., Ltd.

  公开号：EP3992291A1

  公开（公告）日：2022-05-04

  The present invention relates to a novel compound and application thereof in the inhibition of HBV gene expression. The structure of the compound comprises an interfering nucleic acid for inhibiting HBV gene expression, transition points, and delivery chains of the interfering nucleic acid. By means of the delivery chains, two or three N-acetylgalactosamines can be introduced to an antisense strand 3' end of such siRNA, and two or one N-acetylgalactosamine can be correspondingly introduced to a sense strand 5' end, the total number of the introduced N-acetylgalactosamines being four. In vitro and in vivo pharmacological experiments prove that such a novel compound can continuously and efficiently inhibit HBV gene expression.

  本发明涉及一种新型化合物及其在抑制 HBV 基因表达中的应用。该化合物的结构包括用于抑制 HBV 基因表达的干扰核酸、过渡点和干扰核酸的输送链。通过输送链，可以在这种 siRNA 的反义链 3' 端引入两个或三个 N-乙酰半乳糖胺，在义链 5' 端相应地引入两个或一个 N-乙酰半乳糖胺，引入的 N-乙酰半乳糖胺总数为四个。体外和体内药理实验证明，这种新型化合物可以持续有效地抑制 HBV 基因的表达。
• PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
  申请人：Low Philip Stewart

  公开号：US20100324008A1

  公开（公告）日：2010-12-23

  Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.